Invited Sessions

We are pleased to announce details of the Invited Sessions.

I1. Statistical issues in stratified or personalised medicine and biomarker discovery
Monday 22 August, 11.00 - 12.30

 Chairs: Els Goetghebeur, Ghent University and Tim Friede, University of Göttingen 
 Frederick Klauschen, Charité Berlin 
 Applied systems medicine for therapy prediction and clinical trial design in personalized oncology
Jeanine Houwing-Duistermaat, University of Leeds, UK
Methods for integrated analysis of omics datasets: prediction and biology
 Nigel Stallard, University of Warwick
 Adaptive enrichment designs

I2. Infectious disease epidemiology 
Monday 22 August, 14.00 - 15.30

 Chair: Heather Whitaker, Open University 
 Peter Diggle, Lancaster University and University of Liverpool 
 Statistical Methods for real-time monitoring of health outcomes
 Niel Hens, Hasselt
 Inferring time-dependent basic reproduction numbers from serial seroprevalence data on hepatitis A
 Christl Donnelly, Imperial College London
 Outbreak analysis and modelling: the Zika challenge

 I3. Statistical methods in pharmacoepidemiology and drug safety 
 Monday 22 August, 16.00 - 17.30

 Chair: Chris Weir, University of Edinburgh 
 Heather Whitaker, Open University
 Self-controlled case series method
Shahrul Mt-Isa, Merck Sharp & Dohme
The emerging and merging fields of benefit-risk and health technology assessments
Stephen Evans and Elizabeth Williamson, London School of Hygiene and Tropical Medicine
 Pharmacoepidemiology: Right questions? Right answers?

 I4. Meta Analysis and Medical Decision Making
Tuesday 23 August, 09.00 - 10.30 

 Chairs: Julian Higgins, University of Bristol  
 Tom Trikalinos, Brown University
 Decision making under alternative interpretations of the evidence
 Sofia Dias, University of Bristol
 Experiences undertaking complex evidence syntheses for NICE guidelines
 Ewout Steyerberg, Erasmus University Medical Center
 Meta-analysis of prediction models and decision making

 I5. Adaptive designs for oncology clinical trials
 Tuesday 23 August, 11.00 - 12.30

 Chairs: Daniel Sargent, Mayo Clinic and Sarah Zohar, INSERM  
Lindsay Renfro, Mayo Clinic
Bayesian Adaptive Trial Design With Multiple Efficacy Endpoints for Heterogeneous Subpopulations
Matthew Sydes, University College London
Design and implementation of platform trials for biomarker-driven questions
Martin Posch, Medical University of Vienna
A Decision Theoretic Approach to Optimize Clinical Trial Designs for Targeted Therapies

 I6. Research showcase from the MRC Network of Hubs for Trials Methodology  Research 
 Wednesday 24 August, 09.00 - 10.30

 Chairs: Thomas Jaki, Lancaster University 
 Jane Blazeby, University of Bristol 
 The MRC Hubs for Trials Methodology Network: Improving health by improving trials
 Christina Yap, Cancer Research UK Clinical Trials Unit, University of Birmingham
 Practical implementation of an adaptive, Time-to-Event Continual Reassessment Method in a dose-finding oncology trial
 Thomas Jaki, Lancaster University
 TAILoR: Lessons from a multi-arm multi-stage clinical trial in HIV/AIDS
 Andrea Jorgensen, University of Liverpool
 Laying the groundwork for a trial: biomarker identification
 James Wason, MRC Biostatistics Unit, Cambridge
 Novel designs for trials with multiple treatments and biomarkers

 I7. Myths and pitfalls in survival analysis
 Wednesday 24 August, 14.00 - 15.30

 Chairs: Martina Mittlboeck, Medical University of Vienna and Hein Putter, Leiden University Medical Center 
 Niels Keiding, University of Copenhagen
 Prevalent cohort studies and unobserved heterogeneity
 Odd O. Aalen, University of Oslo
 The elusive concept of frailty: A glimpse into survival, heterogeneity and causality
 Jan Beyersman, Ulm University
 Competing risks, immortal time bias: two myths in survival analysis?